AMENDED CLAIM SET:

1. – 11. (cancelled).

12. (currently amended) Process for the preparation of the polymorph form 1 of methyl (S)-(+)-(2chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate of the formula



I.

which comprises providing an "A" type solvent selected from the group consisting of halogenated solvents, ketones, protic solvents, and mixtures thereof and a "B" type solvent selected from the group consisting of ether type solvents, ester type solvents, alkyl hydrocarbons, and mixtures thereof, and

a.) dissolving clopidogrel base in an "A" type solvent, adding sulfuric acid or a mixture of sulfuric acid and an "A" or "B" type solvent to the mixture, adding the obtained mixture containing clopidogrel hydrogensulfate ~~is added~~ to a mixture of a "B" type solvent containing clopidogrel hydrogensulfate polymorph form 1 as a suspension,

or

b.) dissolving clopidogrel base in a mixture of "A" and "B" type solvents, adding clopidogrel hydrogensulfate polymorph form 1 ~~is added~~ to the solution, then adding ~~sulfuric acid or~~ a mixture of sulfuric acid with ~~an "A" or~~ a "B" type solvent to the obtained mixture, and filtering, optionally washing and drying the formed precipitate.

13. (currently amended) Process according to Claim 12 which comprises using ~~less polar aprotic solvents preferably halogenated solvents, more preferably~~ dichloromethane, or

acetone, ~~or protic solvents~~ or mixtures thereof as the "A" type solvent, and using ~~aprotic solvents, preferably ether type solvents, more preferably~~ diethyl ether, tetrahydrofurane, diisopropyl ether, ~~most preferably diisopropyl ether, or dipolar aprotic solvents, preferably ester type solvent, more preferably~~ ethyl acetate, ~~or apolar solvents preferably alkyl hydrocarbons more preferably~~ cyclohexane, hexane, or heptane~~, most preferably cyclohexane~~ as the "B" type solvent.

14. (previously presented) Process according to Claim 12 which comprises dissolving the clopidogrel base in dichloromethane, the obtained mixture is cooled to 0 °C under stirring, adding 96 w/w% of sulfuric acid to the solution, adding the obtained mixture to a suspension of clopidogrel hydrogensulfate of the polymorph 1 form in cyclohexane at 8-10 °C, then filtering, drying the obtained precipitate.

15. (previously presented) Process according to Claim 12 which comprises dissolving the clopidogrel base in dichloromethane, the obtained mixture is cooled to 0 °C under stirring, adding 96 w/w% of sulfuric acid to the solution, adding the obtained mixture to a suspension of clopidogrel hydrogensulfate of the polymorph 1 form in ethyl acetate at 20 °C, then filtering, drying the obtained precipitate.

16. (new) The process of claim 12, wherein the "A" type solvent comprises acetone.

17. (new) The process of claim 12, wherein the "B" type solvent comprises diisopropyl ether.

18. (new) The process of claim 12, wherein the "B" type solvent comprises cyclohexane.